Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial-Reference-Cited by-同舟云学术

Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial

Published:2017-08 Issue: Volume:34 Page:18-23
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Ghouadni Amal,Delaloge Suzette,Lardelli Pilar,Kahatt Carmen,Byrski Tomasz,Blum Joanne L.,Gonçalves Anthony,Campone Mario,Nieto Antonio,Alfaro Vicente,Cullell-Young Martin,Lubinski Jan

Funder

Astra Zeneca

Pharma Mar, S.A

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference18 articles.

1. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study;Schoffski;Eur J Cancer,2011

2. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin;Herrero;Cancer Res,2006

3. Trabectedin as a chemotherapy option for patients with BRCA deficiency;Monk;Cancer Treat Rev,2016

4. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial;Lorusso;Ann Oncol,2016

5. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study;Delaloge;Ann Oncol,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study;ESMO Open;2022-10

2. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds;Frontiers in Pharmacology;2022-09-08

3. Trabectedin in Cancers: Mechanisms and Clinical Applications;Current Pharmaceutical Design;2022-07

4. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL);Gynecologic Oncology;2021-11

5. Breast cancer fibroblasts and cross-talk;Clinica Chimica Acta;2021-10